Pierre-Emmanuel Rautou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2187381/publications.pdf

Version: 2024-02-01

146 papers 14,317 citations

³⁸⁷⁴² 50 h-index

20358 116 g-index

154 all docs

154 docs citations

154 times ranked 24848 citing authors

#	Article	IF	Citations
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
2	Liver sinusoidal endothelial cells: Physiology and role in liver diseases. Journal of Hepatology, 2017, 66, 212-227.	3.7	639
3	Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology, 2010, 52, 1017-1022.	7.3	452
4	Extracellular vesicles in coronary artery disease. Nature Reviews Cardiology, 2017, 14, 259-272.	13.7	392
5	Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: Results of a longitudinal study. Hepatology, 2015, 61, 660-667.	7.3	364
6	Autophagy in liver diseases. Journal of Hepatology, 2010, 53, 1123-1134.	3.7	351
7	Microparticles, Vascular Function, and Atherothrombosis. Circulation Research, 2011, 109, 593-606.	4.5	331
8	Inhibition of MicroRNA-92a Prevents Endothelial Dysfunction and Atherosclerosis in Mice. Circulation Research, 2014, 114, 434-443.	4.5	317
9	Autophagy in liver diseases: Time for translation?. Journal of Hepatology, 2019, 70, 985-998.	3.7	252
10	Microparticles From Human Atherosclerotic Plaques Promote Endothelial ICAM-1–Dependent Monocyte Adhesion and Transendothelial Migration. Circulation Research, 2011, 108, 335-343.	4.5	221
11	Prospective Comparison of Spleen and Liver Stiffness by Using Shear-Wave and Transient Elastography for Detection of Portal Hypertension in Cirrhosis. Radiology, 2015, 275, 589-598.	7.3	190
12	Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease. Journal of Hepatology, 2019, 70, 1278-1291.	3.7	186
13	Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: A cross-over study. Journal of Hepatology, 2011, 55, 794-799.	3.7	177
14	CD40 Ligand+ Microparticles From Human Atherosclerotic Plaques Stimulate Endothelial Proliferation and Angiogenesis. Journal of the American College of Cardiology, 2008, 52, 1302-1311.	2.8	176
15	Management of hepatic vascular diseases. Journal of Hepatology, 2012, 56, S25-S38.	3.7	167
16	Acute Liver Cell Damage in Patients With Anorexia Nervosa: A Possible Role of Starvation-Induced Hepatocyte Autophagy. Gastroenterology, 2008, 135, 840-848.e3.	1.3	165
17	The emerging roles of microvesicles in liver diseases. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 350-361.	17.8	158
18	Autophagy is required for endothelial cell alignment and atheroprotection under physiological blood flow. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E8675-E8684.	7.1	156

#	Article	IF	Citations
19	Mucosal-associated invariant T cells are a profibrogenic immune cell population in the liver. Nature Communications, 2018, 9, 2146.	12.8	152
20	The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study. Liver International, 2010, 30, 725-732.	3.9	149
21	Porto-sinusoidal vascular disease: proposal and description of a novel entity. The Lancet Gastroenterology and Hepatology, 2019, 4, 399-411.	8.1	149
22	Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression. Gut, 2016, 65, 1882-1894.	12.1	140
23	Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver International, 2016, 36, 936-948.	3.9	139
24	Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C. Hepatology, 2014, 60, 823-831.	7.3	135
25	Microparticles: Key Protagonists in Cardiovascular Disorders. Seminars in Thrombosis and Hemostasis, 2010, 36, 907-916.	2.7	127
26	Morphologic Changes in Branch Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas: A Midterm Follow-Up Study. Clinical Gastroenterology and Hepatology, 2008, 6, 807-814.	4.4	117
27	Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis. Gastroenterology, 2018, 155, 1816-1827.e9.	1.3	113
28	A defect in endothelial autophagy occurs in patients with non-alcoholic steatohepatitis and promotes inflammation and fibrosis. Journal of Hepatology, 2020, 72, 528-538.	3.7	113
29	EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. Journal of Hepatology, 2022, 76, 1151-1184.	3.7	112
30	Abnormal Plasma Microparticles Impair Vasoconstrictor Responses in Patients With Cirrhosis. Gastroenterology, 2012, 143, 166-176.e6.	1.3	105
31	Extracellular vesicles as biomarkers in liver diseases: A clinician's point of view. Journal of Hepatology, 2020, 73, 1507-1525.	3.7	105
32	Assessment of portal hypertension and high-risk oesophageal varices with liver and spleen three-dimensional multifrequency MR elastography in liver cirrhosis. European Radiology, 2014, 24, 1394-402.	4.5	103
33	Portal myofibroblasts promote vascular remodeling underlying cirrhosis formation through the release of microparticles. Hepatology, 2015, 61, 1041-1055.	7.3	102
34	A prospective study of the utility of plasma biomarkers to diagnose alcoholic hepatitis. Hepatology, 2017, 66, 555-563.	7.3	91
35	Pregnancy in women with known and treated Budd–Chiari syndrome: Maternal and fetal outcomes. Journal of Hepatology, 2009, 51, 47-54.	3.7	85
36	Primary cilia sensitize endothelial cells to BMP and prevent excessive vascular regression. Journal of Cell Biology, 2018, 217, 1651-1665.	5.2	84

#	Article	IF	Citations
37	Comparative protein expression profiles of hilar and peripheral hepatic cholangiocarcinomas. Journal of Hepatology, 2009, 51, 93-101.	3.7	83
38	Current knowledge in pathophysiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral splanchnic vein thrombosis. Journal of Hepatology, 2019, 71, 175-199.	3.7	80
39	Resolution of liver fibrosis requires myeloid cell–driven sinusoidal angiogenesis. Hepatology, 2015, 61, 2042-2055.	7.3	79
40	Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis. Hepatology, 2016, 63, 1640-1650.	7.3	73
41	Role of the transjugular intrahepatic portosystemic shunt in the management of severe complications of portal hypertension in idiopathic noncirrhotic portal hypertension. Hepatology, 2016, 64, 224-231.	7.3	69
42	Severe hyponatremia is a better predictor of mortality than MELDNa in patients with cirrhosis and refractory ascites. Journal of Hepatology, 2012, 57, 274-280.	3.7	67
43	Gene- and exon-expression profiling reveals an extensive LPS-induced response in immune cells in patients with cirrhosis. Journal of Hepatology, 2013, 58, 936-948.	3.7	66
44	Prognostic Indices for Budd–Chiari Syndrome: Valid for Clinical Studies but Insufficient for Individual Management. American Journal of Gastroenterology, 2009, 104, 1140-1146.	0.4	65
45	Quantification of hepatic steatosis with ultrasound: promising role of attenuation imaging coefficient in a biopsy-proven cohort. European Radiology, 2020, 30, 2293-2301.	4.5	65
46	Bleeding in patients with Budd–Chiari syndrome. Journal of Hepatology, 2011, 54, 56-63.	3.7	61
47	Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study. Journal of Hepatology, 2021, 75, 1026-1033.	3.7	59
48	Changes in Autophagic Response in Patients with Chronic Hepatitis C Virus Infection. American Journal of Pathology, 2011, 178, 2708-2715.	3.8	58
49	The significance of nonobstructive sinusoidal dilatation of the liver: Impaired portal perfusion or inflammatory reaction syndrome. Hepatology, 2015, 62, 956-963.	7.3	54
50	Long-term Outcome and Analysis of Dysfunction of Transjugular Intrahepatic Portosystemic Shunt Placement in Chronic Primary Budd-Chiari Syndrome. Radiology, 2017, 283, 280-292.	7.3	54
51	Microvesicles as risk markers for venous thrombosis. Expert Review of Hematology, 2013, 6, 91-101.	2.2	51
52	Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study. Journal of Hepatology, 2017, 67, 501-507.	3.7	50
53	Type 2 diabetes mellitus as a risk factor for intestinal resection in patients with superior mesenteric vein thrombosis. Liver International, 2014, 34, 1314-1321.	3.9	48
54	Interplay of Inflammation and Endothelial Dysfunction in Bone Marrow Transplantation: Focus on Hepatic Veno-Occlusive Disease. Seminars in Thrombosis and Hemostasis, 2015, 41, 629-643.	2.7	48

#	Article	IF	CITATIONS
55	Nonselective betaâ€blockers and the risk of portal vein thrombosis in patients with cirrhosis: results of a prospective longitudinal study. Alimentary Pharmacology and Therapeutics, 2019, 49, 582-588.	3.7	48
56	Nonâ€invasive evaluation of portal hypertension using shearâ€wave elastography: analysis of two algorithms combining liver and spleen stiffness in 191 patients with cirrhosis. Alimentary Pharmacology and Therapeutics, 2018, 47, 621-630.	3.7	46
57	Quantification of Liver Surface Nodularity at CT: Utility for Detection of Portal Hypertension. Radiology, 2018, 289, 698-707.	7.3	45
58	Prevalence, features and predictive factors of liver nodules in Fontan surgery patients: The VALDIG Fonliver prospective cohort. Journal of Hepatology, 2020, 72, 702-710.	3.7	45
59	Liver Autophagy in Anorexia Nervosa and Acute Liver Injury. BioMed Research International, 2014, 2014, 1-10.	1.9	44
60	Benign and malignant hepatocellular lesions in patients with vascular liver diseases. Abdominal Radiology, 2018, 43, 1968-1977.	2.1	44
61	Pregnancy and Vascular Liver Disease. Journal of Clinical and Experimental Hepatology, 2015, 5, 41-50.	0.9	42
62	No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease. Journal of Hepatology, 2020, 73, 717-718.	3.7	42
63	Erythrocyte-derived microvesicles induce arterial spasms in JAK2V617F myeloproliferative neoplasm. Journal of Clinical Investigation, 2020, 130, 2630-2643.	8.2	42
64	Liver Stiffness by Transient Elastography to Detect Portoâ€6inusoidal Vascular Liver Disease With Portal Hypertension. Hepatology, 2021, 74, 364-378.	7.3	40
65	Levels and Initial Course of Serum Alanine Aminotransferase Can Predict Outcome of Patients With Budd–Chiari Syndrome. Clinical Gastroenterology and Hepatology, 2009, 7, 1230-1235.	4.4	39
66	Characterization of Blood Immune Cells in Patients With Decompensated Cirrhosis Including ACLF. Frontiers in Immunology, 2020, 11, 619039.	4.8	39
67	Endothelial Cell–derived Microparticles Loaded with Iron Oxide Nanoparticles: Feasibility of MR Imaging Monitoring in Mice. Radiology, 2012, 263, 169-178.	7.3	38
68	Ultrasonic fat fraction quantification using <i>in vivo</i> adaptive sound speed estimation. Physics in Medicine and Biology, 2018, 63, 215013.	3.0	38
69	Impact of cardiac function, refractory ascites and beta blockers on the outcome of patients with cirrhosis listed for liver transplantation. Journal of Hepatology, 2020, 72, 463-471.	3.7	38
70	Low specificity of washout to diagnose hepatocellular carcinoma in nodules showing arterial hyperenhancement in patients with Budd-Chiari syndrome. Journal of Hepatology, 2019, 70, 1123-1132.	3.7	37
71	Interaction between the autophagy protein Beclin 1 and Na+,K+-ATPase during starvation, exercise, and ischemia. JCI Insight, 2020, 5, .	5.0	37
72	Role of extracellular vesicles in liver diseases and their therapeutic potential. Advanced Drug Delivery Reviews, 2021, 175, 113816.	13.7	37

#	Article	IF	Citations
73	Hepatocyte tissue factor contributes to the hypercoagulable state in a mouse model of chronic liver injury. Journal of Hepatology, 2016, 64, 53-59.	3.7	36
74	Autosis occurs in the liver of patients with severe anorexia nervosa. Hepatology, 2015, 62, 657-658.	7.3	35
75	Diagnosis of Budd–Chiari syndrome. Abdominal Radiology, 2018, 43, 1896-1907.	2.1	35
76	2D shear wave liver elastography by Aixplorer to detect portal hypertension in cirrhosis: An individual patient data metaâ€analysis. Liver International, 2020, 40, 1435-1446.	3.9	35
77	Hepatocyte microvesicle levels improve prediction of mortality in patients with cirrhosis. Hepatology, 2018, 68, 1508-1518.	7.3	33
78	Circulating microparticle tissue factor activity Is increased in patients with cirrhosis. Hepatology, 2014, 60, 1793-1795.	7.3	31
79	Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses. Blood Advances, 2020, 4, 3708-3715.	5. 2	31
80	Ultraâ€short bowel is an independent risk factor for liver fibrosis in adults with home parenteral nutrition. Liver International, 2018, 38, 174-182.	3.9	30
81	Editorial: G-CSF Therapy for Severe Alcoholic Hepatitis: Targeting Liver Regeneration or Neutrophil Function?. American Journal of Gastroenterology, 2014, 109, 1424-1426.	0.4	29
82	NADPH oxidase depletion in neutrophils from patients with cirrhosis and restoration via toll-like receptor 7/8 activation. Gut, 2018, 67, 1505-1516.	12.1	29
83	Predictors of tumor response after preoperative chemoradiotherapy for rectal adenocarcinomas. Human Pathology, 2011, 42, 1702-1709.	2.0	28
84	Type I interferon signaling in systemic immune cells from patients with alcoholic cirrhosis and its association with outcome. Journal of Hepatology, 2017, 66, 930-941.	3.7	26
85	Pregnancy in idiopathic non-cirrhotic portal hypertension: A multicentric study on maternal and fetal management and outcome. Journal of Hepatology, 2018, 69, 1242-1249.	3.7	26
86	LPS-TLR4 Pathway Mediates Ductular Cell Expansion in Alcoholic Hepatitis. Scientific Reports, 2016, 6, 35610.	3.3	25
87	Endothelial autophagic flux hampers atherosclerotic lesion development. Autophagy, 2018, 14, 173-175.	9.1	24
88	Comparison of endothelial promoter efficiency and specificity in mice reveals a subset of Pdgfbâ€positive hematopoietic cells. Journal of Thrombosis and Haemostasis, 2019, 17, 827-840.	3.8	24
89	Del-etion of Microvesicles From the Circulation. Circulation, 2012, 125, 1601-1604.	1.6	22
90	Evidence for an Association Between Intrahepatic Vascular Changes and the Development of Hepatopulmonary Syndrome. Chest, 2019, 155, 123-136.	0.8	21

#	Article	IF	Citations
91	Acute extrahepatic infectious or inflammatory diseases are a cause of transient mosaic pattern on CT and MR imaging related to sinusoidal dilatation of the liver. European Radiology, 2016, 26, 3094-3101.	4.5	19
92	Understanding the Similarities and Differences between Hepatic and Pulmonary Veno-Occlusive Disease. American Journal of Pathology, 2019, 189, 1159-1175.	3.8	19
93	Magnetic tagging of cell-derived microparticles: new prospects for imaging and manipulation of these mediators of biological information. Nanomedicine, 2010, 5, 727-738.	3.3	18
94	Venous thrombosis and predictors of relapse in eosinophil-related diseases. Scientific Reports, 2021, 11, 6388.	3.3	18
95	Bleeding risk of variceal band ligation in extrahepatic portal vein obstruction is not increased by oral anticoagulation. European Journal of Gastroenterology and Hepatology, 2018, 30, 563-568.	1.6	17
96	Short―and Longâ€Term Outcomes of Liver Resection for Intrahepatic Cholangiocarcinoma Associated with the Metabolic Syndrome. World Journal of Surgery, 2019, 43, 2048-2060.	1.6	17
97	Hepatitis C virus eradication followed by HBeAg to anti-HBe seroconversion after pegylated interferon-??2b plus ribavirin treatment in a patient with hepatitis B and C coinfection. European Journal of Gastroenterology and Hepatology, 2006, 18, 1019-1022.	1.6	16
98	Pre-therapy liver transcriptome landscape in Indian and French patients with severe alcoholic hepatitis and steroid responsiveness. Scientific Reports, 2017, 7, 6816.	3.3	16
99	Performance of liver surface nodularity quantification for the diagnosis of portal hypertension in patients with cirrhosis: comparison between MRI with hepatobiliary phase sequences and CT. Abdominal Radiology, 2020, 45, 365-372.	2.1	16
100	Systemic inflammation as a risk factor for portal vein thrombosis in cirrhosis: a prospective longitudinal study. European Journal of Gastroenterology and Hepatology, 2021, 33, e108-e113.	1.6	16
101	Similar performance of liver stiffness measurement and liver surface nodularity for the detection of portal hypertension in patients with hepatocellular carcinoma. JHEP Reports, 2020, 2, 100147.	4.9	15
102	Elastography improves accuracy of early hepato-biliary complications diagnosis after allogeneic stem cell transplantation. Haematologica, 2021, 106, 2374-2383.	3.5	14
103	Idiopathic nonâ€cirrhotic portal hypertension: the tip of the obliterative portal venopathies iceberg?. Liver International, 2016, 36, 325-327.	3.9	11
104	Lack of clinical or haemodynamic rebound after abrupt interruption of betaâ€blockers in patients with cirrhosis. Alimentary Pharmacology and Therapeutics, 2016, 43, 966-973.	3.7	11
105	Quantitative Imaging in Diffuse Liver Diseases. Seminars in Liver Disease, 2017, 37, 243-258.	3.6	11
106	Abdominal Surgery in Patients With Idiopathic Noncirrhotic Portal Hypertension: A Multicenter Retrospective Study. Hepatology, 2019, 70, 911-924.	7.3	11
107	Hepatobiliary MR contrast agents are useful to diagnose hepatocellular carcinoma in patients with Budd-Chiari syndrome. JHEP Reports, 2020, 2, 100097.	4.9	11
108	Contrastâ€enhanced CT and liver surface nodularity for the diagnosis of portoâ€sinusoidal vascular disorder: A caseâ€control study. Hepatology, 2022, 76, 418-428.	7.3	11

#	Article	IF	CITATIONS
109	Computed Tomography-Derived Liver Surface Nodularity and Sarcopenia as Prognostic Factors in Patients with Resectable Metabolic Syndrome-Related Hepatocellular Carcinoma. Annals of Surgical Oncology, 2021, 28, 405-416.	1.5	10
110	Portal vein recanalisation alone to treat severe portal hypertension in non-cirrhotic patients with chronic extrahepatic portal vein obstruction. JHEP Reports, 2022, 4, 100511.	4.9	10
111	Impact of SARS-CoV-2 Pandemic on Vascular Liver Diseases. Clinical Gastroenterology and Hepatology, 2022, 20, 1525-1533.e5.	4.4	9
112	Endothelial progenitor cells in cirrhosis: The more, the merrier?. Journal of Hepatology, 2012, 57, 1163-1165.	3.7	8
113	Liver surface nodularity on non-contrast MRI identifies advanced fibrosis in patients with NAFLD. European Radiology, 2022, 32, 1781-1791.	4.5	8
114	Circulating platelet derived microparticles are not increased in patients with cirrhosis. Journal of Hepatology, 2013, 59, 912.	3.7	7
115	Patients with NAFLD do not have severe portal hypertension in the absence of cirrhosis. Journal of Hepatology, 2021, 74, 1269-1270.	3.7	7
116	Ischemic cholangiopathy: An update. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 486-490.	1.5	7
117	Performance of non-invasive biomarkers compared with invasive methods for risk prediction of posthepatectomy liver failure in hepatocellular carcinoma. British Journal of Surgery, 2022, 109, 455-463.	0.3	7
118	lloprost Use in Patients with Persistent Intestinal Ischemia Unsuitable for Revascularization. Annals of Vascular Surgery, 2017, 42, 128-135.	0.9	6
119	Endothelial dysfunction markers predict short-term mortality in patients with severe alcoholic hepatitis. Hepatology International, 2021, 15, 1006-1017.	4.2	6
120	Multicenter study on recent portal venous system thrombosis associated with cytomegalovirus disease. Journal of Hepatology, 2022, 76, 115-122.	3.7	6
121	MR imaging features and long-term evolution of benign focal liver lesions in Budd-Chiari syndrome and Fontan-associated liver disease. Diagnostic and Interventional Imaging, 2022, 103, 111-120.	3.2	6
122	Porto-sinusoidal vascular disease. Vascular liver diseases: Position papers from the francophone network for vascular liver diseases, the French Association for the Study of the Liver (AFEF), and ERN-rare liver. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 447-451.	1.5	5
123	Benefits of molecular profiling with next-generation sequencing for the diagnosis and prognosis of myeloproliferative neoplasms in splanchnic vein thrombosis. Journal of Hepatology, 2021, 74, 251-252.	3.7	5
124	Cirrhosis regression: extrahepatic angiogenesis and liver hyperarterialization persist. Clinical Science, 2018, 132, 1341-1343.	4.3	4
125	Benign and malignant hepatocellular lesions in patients with vascular liver disease. Clinical Liver Disease, 2014, 3, 122-125.	2.1	3
126	Arterial hypertension as an uninvited player in hepatic stiffness?. American Journal of Physiology - Renal Physiology, 2016, 311, G942-G944.	3.4	3

#	Article	IF	CITATIONS
127	Endothelial Autophagy Does Not Influence Venous Thrombosis in Mice. Thrombosis and Haemostasis, 2018, 118, 1113-1115.	3.4	3
128	Endothelial JAK2 does not enhance liver lesions in mice with Budd-Chiari syndrome. Journal of Hepatology, 2018, 68, 1086-1087.	3.7	3
129	Angioplasty with stenting for Budd-Chiari syndrome. The Lancet Gastroenterology and Hepatology, 2019, 4, 657-659.	8.1	3
130	Managing periprocedural thrombocytopenia in cirrhosis: Aiming for a safety window. Journal of Hepatology, 2014, 61, 1199-1201.	3.7	2
131	Budd-Chiari syndrome. Clinical Liver Disease, 2014, 3, 133-136.	2.1	2
132	Reply to: â€~â€~Splenic artery aneurysms, portal hypertension and pregnancyâ€. Journal of Hepatology, 2019, 70, 1026-1027.	3.7	2
133	Microcirculatory changes in the liver of patients with refractory ascites and their relationship with diabetes and alcohol. European Journal of Gastroenterology and Hepatology, 2020, Publish Ahead of Print, .	1.6	2
134	Role of Imaging in the Study of Vascular Disorders of the Liver. , 2022, , 15-33.		2
135	Syndrome deÂBudd-Chiari primitif. Sang Thrombose Vaisseaux, 2010, 22, 201-208.	0.1	1
136	NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF VASCULAR LIVER DISEASES. Clinics and Research in Hepatology and Gastroenterology, 2021, 46, 101764.	1.5	1
137	Imaging-guided interventions modulating portal venous flow: evidence and controversies. JHEP Reports, 2022, , 100484.	4.9	1
138	Dysphagia in a Patient With Recurrent Bilateral Eyelid Ptosis. Gastroenterology, 2010, 139, 1835-2226.	1.3	0
139	Idiopathic Non-cirrhotic Portal Hypertension and Close Entities: a Need for Clarifying Terminology. Current Hepatology Reports, 2017, 16, 237-240.	0.9	O
140	Reply to: "Calreticulin mutations and their importance in Budd-Chiari syndrome― Journal of Hepatology, 2017, 67, 1112-1113.	3.7	0
141	REPLY:. Hepatology, 2021, 74, 2317-2318.	7.3	O
142	REPLY:. Hepatology, 2021, 74, 2911-2912.	7.3	0
143	Liver Disease; Hemostasis and Coagulation Disorders. , 2020, , 418-428.		O
144	Pregnancy in Vascular Liver Disease. , 2022, , 237-248.		0

#	Article	IF	CITATIONS
145	Role of Liver Biopsy in the Study of Vascular Disorders of the Liver. , 2022, , 3-13.		0
146	Reply. Hepatology, 2022, 76, E55-E56.	7.3	0